Oral antipsychotic prescribing and association with neighbourhood-level socioeconomic status: analysis of time trend of routine primary care data in England, 2011-2016.
Antipsychotics
Prescribing trends
Primary care
Severe mental illness
Journal
Social psychiatry and psychiatric epidemiology
ISSN: 1433-9285
Titre abrégé: Soc Psychiatry Psychiatr Epidemiol
Pays: Germany
ID NLM: 8804358
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
19
06
2019
accepted:
09
10
2019
pubmed:
21
10
2019
medline:
25
8
2020
entrez:
21
10
2019
Statut:
ppublish
Résumé
Increasing rates of antipsychotic prescribing have been reported previously, particularly for second-generation antipsychotics (SGAs), which are generally better tolerated than the older first-generation antipsychotics (FGAs). Prescribers, however, may exert bias, favouring prescriptions of novel drugs for patients of higher socioeconomic status (SES). We aimed to examine time trends in: (1) prescriptions of oral FGAs vs. SGAs and (2) associations between antipsychotic prescriptions and neighbourhood-level SES in England between 2011 and 2016. We used publicly available data for prescriptions made in primary care and linked general practices' postcodes with the Index of Multiple Deprivation (IMD) as a measure for neighbourhood-level SES. Absolute numbers of antipsychotic prescriptions were calculated. Linear regression analysis was used to examine the association of SGA vs. FGA prescription pattern with time and with SES. A total of 27,486,000 oral antipsychotics were prescribed during the study period, mostly SGAs (n = 21,700,000; 78.9%). There was a significant increase in the ratio of SGA/FGA prescriptions over time (β = 0.376, 95% CI 0.277-0.464, P < 0.001). Individual FGAs were increasingly prescribed in areas of lower SES and the converse for SGAs except amisulpride. During the study period, a significantly larger proportion of total SGA prescriptions relative to total FGAs were made in areas of higher SES (β = 0.182, 95% CI 0.117-0.249, P < 0.001). Prescriptions of antipsychotics continue to rise overall, with SGAs taking preference especially in areas of higher SES. The pattern of antipsychotic prescription favouring people in areas of lower social deprivation carries implications on inequalities even among sub-groups of people with mental disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Increasing rates of antipsychotic prescribing have been reported previously, particularly for second-generation antipsychotics (SGAs), which are generally better tolerated than the older first-generation antipsychotics (FGAs). Prescribers, however, may exert bias, favouring prescriptions of novel drugs for patients of higher socioeconomic status (SES). We aimed to examine time trends in: (1) prescriptions of oral FGAs vs. SGAs and (2) associations between antipsychotic prescriptions and neighbourhood-level SES in England between 2011 and 2016.
METHODS
METHODS
We used publicly available data for prescriptions made in primary care and linked general practices' postcodes with the Index of Multiple Deprivation (IMD) as a measure for neighbourhood-level SES. Absolute numbers of antipsychotic prescriptions were calculated. Linear regression analysis was used to examine the association of SGA vs. FGA prescription pattern with time and with SES.
RESULTS
RESULTS
A total of 27,486,000 oral antipsychotics were prescribed during the study period, mostly SGAs (n = 21,700,000; 78.9%). There was a significant increase in the ratio of SGA/FGA prescriptions over time (β = 0.376, 95% CI 0.277-0.464, P < 0.001). Individual FGAs were increasingly prescribed in areas of lower SES and the converse for SGAs except amisulpride. During the study period, a significantly larger proportion of total SGA prescriptions relative to total FGAs were made in areas of higher SES (β = 0.182, 95% CI 0.117-0.249, P < 0.001).
CONCLUSION
CONCLUSIONS
Prescriptions of antipsychotics continue to rise overall, with SGAs taking preference especially in areas of higher SES. The pattern of antipsychotic prescription favouring people in areas of lower social deprivation carries implications on inequalities even among sub-groups of people with mental disorders.
Identifiants
pubmed: 31630215
doi: 10.1007/s00127-019-01793-9
pii: 10.1007/s00127-019-01793-9
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
165-173Références
Aust N Z J Psychiatry. 2007 Oct;41(10):809-18
pubmed: 17828654
Pharmacopsychiatry. 2012 Nov;45(7):261-8
pubmed: 22648306
Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26
pubmed: 22009159
Br J Clin Pharmacol. 2003 Nov;56(5):569-75
pubmed: 14651732
Arch Gen Psychiatry. 2003 Jun;60(6):553-64
pubmed: 12796218
J Am Med Dir Assoc. 2014 Oct;15(10):706-18
pubmed: 25112229
Int J Bipolar Disord. 2013 Jun 21;1:9
pubmed: 25505676
Compr Psychiatry. 2016 Apr;66:59-66
pubmed: 26995237
Int Clin Psychopharmacol. 2014 Sep;29(5):288-95
pubmed: 24323200
BMC Med Ethics. 2017 Mar 1;18(1):19
pubmed: 28249596
Eur Psychiatry. 2000 May;15(3):220-6
pubmed: 10881220
PLoS One. 2011;6(12):e28725
pubmed: 22163329
Fam Pract. 2001 Apr;18(2):167-73
pubmed: 11264267
Lancet. 2009 Jan 3;373(9657):31-41
pubmed: 19058842
Psychiatry Res. 2005 Feb 28;133(2-3):277-80
pubmed: 15741003
BMJ Open. 2014 Dec 18;4(12):e006135
pubmed: 25524544
Soc Psychiatry Psychiatr Epidemiol. 2009 Apr;44(4):265-71
pubmed: 18836884
J Clin Pharm Ther. 2002 Dec;27(6):441-51
pubmed: 12472984
Br J Gen Pract. 2018 Mar;68(668):e225-e233
pubmed: 29440012
Lancet. 2013 Sep 14;382(9896):951-62
pubmed: 23810019
Am J Psychiatry. 1983 Feb;140(2):166-70
pubmed: 6849427
Psychiatr Bull (2014). 2014 Apr;38(2):54-7
pubmed: 25237499
Br J Psychiatry. 2012 May;200(5):393-8
pubmed: 22442100
Soc Sci Med. 1993 Jun;36(11):1473-82
pubmed: 8511635
Psychiatr Serv. 2014 Mar 1;65(3):315-22
pubmed: 24337224
PLoS One. 2012;7(3):e31660
pubmed: 22457710
Pharmacoepidemiol Drug Saf. 2012 Feb;21(2):161-9
pubmed: 21858898
Acta Psychiatr Scand. 2010 Jan;121(1):4-10
pubmed: 20059452
J Clin Psychopharmacol. 2016 Aug;36(4):355-71
pubmed: 27307187
Schizophr Res. 2015 Dec;169(1-3):406-411
pubmed: 26481616
Transl Psychiatry. 2016 May 03;6:e796
pubmed: 27138795
Am J Psychiatry. 2002 Feb;159(2):180-90
pubmed: 11823257
Health Technol Assess. 2017 Sep;21(49):1-56
pubmed: 28869006
Schizophr Res. 2013 Oct;150(1):274-80
pubmed: 23953217